Sugi Predict

Sugi Predict / Compounds / SCHEMBL2597259

SCHEMBL2597259

SCHEMBL2597259

CCc1cc2[nH]c(=O)n(N(C(=O)OCCOC)S(C)(=O)=O)c(=O)c2cc1-c1ccnn1C

nearest known ligand 0.33

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.33
▸ KDM4E B2RXH2 6/20 0.33
▸ GLA P06280 6/20 0.33
▸ HPGD P15428 6/20 0.33
▸ HSD17B10 Q99714 5/20 0.33
▸ GAA P10253 5/20 0.33
▸ PKM P14618 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ IMPDH2 P12268 2/20 0.32
▸ HTR2A P28223 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597242 0.93 HAVCR2 (0.30) KDM4EHSD17B10
SCHEMBL2597118 0.92 CYP1A2 (0.33) ALDH1A1KDM4EGLAHPGDHSD17B10
SCHEMBL2597375 0.92 HAVCR2 (0.33) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL2597234 0.91 KDM4E (0.34) ALDH1A1KDM4EGLAHPGDHSD17B10
SCHEMBL2597362 0.91 KDM4E (0.30) ALDH1A1KDM4EGLAHPGDHSD17B10
SCHEMBL2597260 0.91 IMPDH2 (0.33) ALDH1A1KDM4EGLAHPGDHSD17B10
SCHEMBL2597245 0.90 KDM4E (0.34) ALDH1A1KDM4EGLAHPGDHSD17B10
SCHEMBL2597208 0.89 KDM4E (0.34) ALDH1A1KDM4EGLAHPGDHSD17B10
SCHEMBL2597178 0.89 KDM4E (0.31) ALDH1A1KDM4E
SCHEMBL2597072 0.88 LIPG (0.37) ALDH1A1KDM4EGLAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571865-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES Novartis AG (CH) 2013-03-27 — — EP claimed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US claimed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO claimed
EP-2571865-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES Novartis AG (CH) 2013-03-27 — — EP disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO disclosed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES GRIK2, GRIK1, GRIK4 ALDH1A1 387/4885KDM4E 784/4885GLA 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.